
|Videos|July 23, 2021
First Vyluma product tackles pediatric myopia
Advertisement
Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Some red light therapy devices may exceed safety levels for myopia control, study suggests
2
What to know about the most recent treatment and management developments in AMD
3
No myopia progression reported on average in 6-month trial assessing MiYOSMART iQ spectacle lenses
4
Comanagement to take center stage at EnVision Summit 2026
5




























